The U.S. automotive market had a wild 2025, thanks to the uncertain climate under President Donald Trump's mercurial tariff policy. Still, analysts at Bank of America believe that at least three U.S. car companies are worth investing in. Carmakers such as Ford played the change in the U.S. economic policy perfectly. Ford rode dealer incentives, combined with consumer anxiety about tariffs, to become the top-selling brand in the U.S. during the year’s first half. Ford said total sales in the second quarter ...

Core Viewpoint - Morgan Stanley is set to eliminate 2,500 jobs globally, representing approximately 3% of its workforce, as part of a strategic reshaping of its operations [1][2]. Group 1: Job Cuts and Financial Performance - The layoffs will impact employees across wealth management, investment banking, and investment management divisions [1]. - This decision follows a record year for Morgan Stanley in 2025, where the bank reported historic annual revenue in its investment banking and trading units [2]. Group 2: Industry Trends - The job cuts align with broader industry trends where financial institutions are increasingly adopting artificial intelligence and automation, leading to cost reductions and workforce realignments [2]. - Morgan Stanley is part of a growing list of banks adjusting staffing levels despite strong financial performance, indicating a shift in priorities towards technology integration and operational efficiency [3]. Group 3: Market Reaction - Following the announcement, shares of Morgan Stanley declined nearly 2% on Thursday morning [3].

Core View - The analyst has revised the rating for Keurig Dr Pepper (KDP) from hold to a more positive outlook due to changes observed in Q4, particularly in the core US Refreshment Beverages segment [1]. Company Analysis - The company has shown potential for long-term growth, with a focus on fundamental analysis and identifying undervalued opportunities [1]. - The investment strategy emphasizes acquiring quality companies at a discount to their intrinsic value and holding them for compounding earnings and shareholder returns [1].

Mark Steven Fogel: Good morning, everyone, and thank you for joining our call. Today, I will provide an overview of our loan operations, real estate investments, and the health of the investment portfolio, while Eldron C. Blackwell, our CFO, will discuss the financial statements, liquidity condition, book value, and operating results for the fourth quarter 2025. Of course, we look forward to your questions at the end of our prepared remarks. The ACRES team remains focused on executing on our business strate ...

Group 1 - Oracle (ORCL) shares increased by $3.09, or 2.07%, reaching approximately $152.10 [1] - Options trading volume was relatively light with 74,000 contracts traded, and calls outnumbered puts, resulting in a put/call ratio of 0.45, significantly lower than the typical level of 1.27 [1] - Implied volatility (IV30) decreased by 1.45 to around 71.13, which is in the highest 10% of observations over the past year, indicating an expected daily price movement of $6.82 [1] Group 2 - The put-call skew has steepened, reflecting increased demand for downside protection [1] - Oracle is scheduled to report earnings after the market closes on March 10, 2026 [1] - The options market is pricing in a 50% probability of a price movement greater than 10.71%, equating to $16.30 [1]

Core Insights - MasterCraft Boat (MCFT) has announced a strategic partnership with Yellow Sun Marine, designating it as an authorized dealership in Turks & Caicos [1] - Wake to Wake, a sister company of Yellow Sun Marine, is transitioning its charter fleet exclusively to MasterCraft towboats, enhancing the on-water experiences in the region [1] Company Developments - The partnership with Yellow Sun Marine aims to expand MasterCraft's market presence in the Turks & Caicos [1] - The exclusive transition of Wake to Wake's charter fleet to MasterCraft towboats signifies a commitment to quality and brand alignment in the boating industry [1]

Fed terminates enforcement action imposed on Wells Fargo due to fake accounts scandal | ReutersSkip to main contentExclusive news, data and analytics for financial market professionalsLearn more aboutRefinitivItem 1 of 2 People walk by a Wells Fargo bank branch in New York City, U.S., June 4, 2025. REUTERS/Kylie Cooper[1/2]People walk by a Wells Fargo bank branch in New York City, U.S., June 4, 2025. REUTERS/Kylie Cooper Purchase Licensing Rights, opens new tab- CompaniesWells Fargo & CoFollowWASHINGTON, Ma ...

Core Viewpoint - Emerging Growth Research maintains a Buy-Extended rating and a 12-month price target of $3.90 for Immuron Limited following the release of its first-half fiscal year 2026 financial results and strategic update [1] Financial Performance - Immuron reported global product revenue of AUD $4.18 million for the six months ended December 31, 2025, reflecting approximately 5% growth year-over-year [1] - Australian revenue increased by 13% year-over-year, while U.S. revenue rose by 17%. Canadian revenue declined due to distributor-level dynamics [1] - Gross margin for the first half was 63.4%, and the operating margin improved due to lower general and administrative and research and development expenses [1] - Net loss narrowed to AUD $(1.92) million compared to AUD $(2.49) million in the prior-year period [1] Capital Position - Immuron raised approximately AUD $7.3 million through its at-the-market facility, increasing its cash balance to approximately AUD $10.0 million as of December 31, 2025 [1] - This capital position is expected to provide operational runway into 2027 [1] Product Development - The December 2025 launch of ProIBS® in Australia contributed initial revenue, with expanded distribution expected to support incremental revenue growth over time [1] - Immuron's clinical-stage pipeline includes IMM-529, which received U.S. FDA authorization to proceed into a randomized, placebo-controlled Phase 2 trial in Australia [1] - The company is seeking development partners for both IMM-529 and IMM-124E to advance clinical development [1] Rating Justification - The maintained Buy-Extended rating reflects the combination of commercial revenue, a strengthened balance sheet, and longer-term clinical development potential, balanced against funding requirements and typical biotechnology development risks [1] - The $3.90 price target is based on a peer-group EV/Revenue valuation methodology applied to Immuron's trailing twelve-month revenue [1]

Loop Capital initiates coverage on the AI silicon stock with a Buy rating and $250 price target. ...

It's not just Nvidia shares that might struggle if a broader market correction is sparked by an AI-specific meltdown. In fact, after its recent run-up, there's another name that might technically be even more vulnerable to a sweeping setback if investors suddenly panic. That's ASML Holding (NASDAQ: ASML).And it's not a wild concern. Although plenty of competition is finally surfacing, Nvidia-made processors remain the computing heart and soul of most new AI data centers. If the artificial intelligence indus ...